Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43857   clinical trials with a EudraCT protocol, of which   7284   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2021-004325-80
    Sponsor's Protocol Code Number:ANAVEX2-73-AD-EP-004
    National Competent Authority:Netherlands - Competent Authority
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2021-10-07
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedNetherlands - Competent Authority
    A.2EudraCT number2021-004325-80
    A.3Full title of the trial
    Open Label Extension Study for Patients with Early Alzheimer’s Disease (AD) Enrolled in Study ANAVEX2-73-AD-004
    Open label extensie studie voor patienten met de ziekte van Alzheimer in een vroege fase die geïncludeerd zijn in de ANAVEX2-73-AD-004 studie
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    ANAVEX2-73 Extension Study for treatment in AD
    Extensie studie met ANAVEX2-73 voor de behandeling van AD
    A.3.2Name or abbreviated title of the trial where available
    ANAVEX2-73 AD Extension Study
    A.4.1Sponsor's protocol code numberANAVEX2-73-AD-EP-004
    A.5.2US NCT (ClinicalTrials.gov registry) numberNCT04314934
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorAnavex Germany GmbH
    B.1.3.4CountryGermany
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportAnavex Germany GmbH
    B.4.2CountryGermany
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationAnavex
    B.5.2Functional name of contact pointStephan Toutain
    B.5.3 Address:
    B.5.3.1Street AddressAm Klopferspitz 19a
    B.5.3.2Town/ cityPlanegg
    B.5.3.3Post code82152
    B.5.3.4CountryGermany
    B.5.6E-mailstoutain@anavexcorp.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameANAVEX2-73
    D.3.2Product code ANAVEX2-73
    D.3.4Pharmaceutical form Capsule
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNANAVEX2-73
    D.3.9.2Current sponsor codeANAVEX2-73
    D.3.9.3Other descriptive nameANA001xHCl (Syntagon) or VEXA-04 (Patheon)
    D.3.9.4EV Substance CodeAS1
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number10
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameANAVEX2-73
    D.3.4Pharmaceutical form Capsule
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNANAVEX2-73
    D.3.9.2Current sponsor codeANAVEX2-73
    D.3.9.4EV Substance CodeAS2
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number20
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 3
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameANAVEX2-73
    D.3.4Pharmaceutical form Oral solution
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNANAVEX2-73
    D.3.9.2Current sponsor codeANAVEX2-73
    D.3.9.3Other descriptive nameC19H23NO-HC1
    D.3.9.4EV Substance CodeAS3
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number5
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Alzheimer's Disease
    Ziekte van Alzheimer
    E.1.1.1Medical condition in easily understood language
    Dementia
    Dementie
    E.1.1.2Therapeutic area Diseases [C] - Nervous System Diseases [C10]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level LLT
    E.1.2Classification code 10001896
    E.1.2Term Alzheimer's disease
    E.1.2System Organ Class 100000004852
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To continue assessing the safety and tolerability of ANAVEX2-73.
    Safety and Tolerability Measures:
    - Physical examination
    - Vital signs (heart rate, respiratory rate, systolic blood pressure [SBP], diastolic blood pressure [DBP], pulse oximetry, and oral body temperature)
    - Graded AEs according to common Terminology Criteria for Adverse Events (CTCAE) V4.0.3
    - 12-lead ECG
    - Columbia-Suicide Severity Rating Scale (C-SSRS)
    - Clinical laboratory tests (hematology including coagulation, clinical chemistry including lipid panel, and urinalysis)
    - Concomitant medication documentation
    Continueren met het beoordelen van de veiligheid en verdraagbaarheid van ANAVEX2-73.
    Metingen voor veiligheid en verdraagbaarheid:
    • Lichamelijk onderzoek
    • Vitale functies (hartslag, ademhalingsfrequentie, systolische en diastolische bloeddruk, pulse oximetrie en orale lichaamstemperatuur
    • Gegradeerde AEs volgend de Terminology Criteria for Adverse Events (CTCAE) v4.0.3
    • 12-lead ECG
    • Columbia-Suicide Severity Rating Scale (C-SSRS)
    • Laboratorium onderzoek (hematologie, stolling, klinische chemie inclusief lipiden panel en urine analyse)
    • Documentatie van gelijktijdig genomen medicatie
    E.2.2Secondary objectives of the trial
    • Observation of P-tau blood level concentration
    • To determine whether ANAVEX2-73 modifies cognition, behavior, or QoL, according to the following standardized measures commonly used in AD:
    - Change from baseline to week 96 in ADAS-Cog
    - Change from baseline to week 96 in ADCS-ADL
    - Change from baseline to week 96 in MMSE
    - Change from baseline to week 96 in NPI-Q
    - Change from baseline to week 96 in ZBI
    - Change from baseline to week 96 in QoL-AD
    • Observeren van de P-tau bloedspiegel
    • Bepalen of ANAVEX2-73 cognitie, gedrag of QoL wijzigt, volgens aan de volgende gestandaardiseerde metingen die vaak worden gebruikt in AD:
    - Verandering vanaf baseline tot week 96 in ADAS-Cog
    - Verandering vanaf baseline tot week 96 in ADCS-ADL
    - Verandering vanaf baseline tot week 96 in MMSE
    - Verandering vanaf baseline tot week 96 in NPI-Q
    - Verandering vanaf baseline tot week 96 in ZBI
    - Verandering vanaf baseline tot week 96 in QoL-AD.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Previous completion of participation in the ANAVEX2-73-AD-004 double-blind
    study.
    2. Participants may be either outpatients, or residents of an assisted-living facility.
    3. Participants must have a designated study partner, who spends at least 10 hr per week with the participant, in order for assessments (e.g., carer burden instruments) to be completed with sufficient knowledge of the participant.
    4. No suicidal ideation of type 4 or 5 in the Columbia Suicide Severity Rating Scale (CSSRS) in the past 3 months (i.e., active suicidal thought(s) with intent but without specific plan, or active suicidal thought(s) with plan and intent) OR suicidal behavior in the past 2 years (i.e., actual attempt, interrupted attempt, aborted attempt, or preparatory acts or behavior).
    5. Confirmation from the participant that, if of childbearing potential, is not pregnant through urine pregnancy testing.
    1. Eerdere voltooiing van deelname aan de ANAVEX2-73-AD-004 dubbelblind studie.
    2. Deelnemers kunnen zowel poliklinisch zijn als bewoners van begeleid wonen.
    3. Deelnemers moeten een aangewezen studiepartner hebben, die minimaal 10 uur per week doorbrengt met de deelnemer, zodat beoordelingen (bijv. instrumenten voor mantelzorg) gedaan kunnen worden met voldoende kennis over de deelnemer.
    4. Geen type 4 of 5 zelfmoordgedachten volgens de Columbia Suicide Severity Rating Scale (CSSRS) in de afgelopen 3 maanden (d.w.z. actieve zelfmoordgedachten met intentie maar zonder specifiek plan, of actieve suïcidale gedachten met plan en intentie) OF suïcidaal gedrag in de afgelopen 2 jaar (d.w.z. daadwerkelijke poging, onderbroken poging, afgebroken poging, of voorbereidende handelingen of gedrag).
    5. Bevestiging van de deelnemer dat deze, indien in de vruchtbare leeftijd, niet zwanger is door middel van urine-zwangerschapstests.
    E.4Principal exclusion criteria
    1. Adverse events (AEs) from the previous study (ANAVEX2-73-AD-004) that have
    not resolved, are moderate or severe, judged to be possibly related or related to study drug, and considered by the investigator to be a contraindication to extension study participation.
    2. Any condition or laboratory abnormality that would make the subject, in the judgment of the investigator, unsuitable for the study.
    3. Significant history of drug addiction (with the exception of nicotine dependence) or abuse (including alcohol, as defined in DSM-5 or in the opinion of the investigator) within the last two years prior to informed consent, or a positive urine drug screen for cocaine, opioid, phencyclidine (PCP), amphetamine or marijuana at baseline. Prescription medication yielding a positive drug screen are acceptable except for tricyclic antidepressants.
    4. Any known hypersensitivity to any of the excipients contained in the study drug formulation.
    1. Ongewenste voorvallen (AE's) uit de vorige studie (ANAVEX2-73-AD-004) die niet zijn verdwenen, matig of ernstig zijn, mogelijk verband houden met of gerelateerd zijn aan het onderzoeksmiddel en door de onderzoeker als een contra-indicatie worden beschouwd studiedeelname te verlengen.
    2. Elke aandoening of laboratoriumafwijking die de proefpersoon, naar het oordeel van de onderzoeker, ongeschikt zou maken voor het onderzoek.
    3. Significante voorgeschiedenis van drugsverslaving (met uitzondering van nicotineverslaving) of drugsmisbruik (inclusief alcohol, zoals gedefinieerd in DSM-5 of naar de mening van de onderzoeker) in de laatste twee jaar voorafgaand aan toestemming, of een positieve urine drugscreening op cocaïne, opioïde, fencyclidine (PCP), amfetamine of marihuana bij de baseline. Geneesmiddelen op recept die een positieve drugscreening opleveren, zijn acceptabel, behalve voor tricyclische antidepressiva.
    4. Elke bekende overgevoeligheid voor de hulpstoffen in de formulering van het onderzoeksmiddel.
    E.5 End points
    E.5.1Primary end point(s)
    To continue assessing the safety and tolerability of ANAVEX2-73.
    Safety and Tolerability Measures:
    1. Physical and neurological examination
    2. Vital signs (heart rate, respiratory rate, systolic blood pressure [SBP], diastolic blood pressure [DBP], and oral body temperature)
    3. Graded Adverse Events (AEs) according to common Terminology Criteria for
    Adverse Events (CTCAE) V4.0.3
    4. 12-lead ECG
    5. Clinical laboratory tests (hematology, coagulation, clinical chemistry, and
    urinalysis)
    6. Columbia-Suicide Severity Rating Scale (C-SSRS)
    7. Documenting concomitant medications
    Continueren met het beoordelen van de veiligheid en verdraagbaarheid van ANAVEX2-73.
    Metingen voor veiligheid en verdraagbaarheid:
    • Lichamelijk onderzoek
    • Vitale functies (hartslag, ademhalingsfrequentie, systolische en diastolische bloeddruk, pulse oximetrie en orale lichaamstemperatuur
    • Gegradeerde AEs volgend de Terminology Criteria for Adverse Events (CTCAE) v4.0.3
    • 12-lead ECG
    • Columbia-Suicide Severity Rating Scale (C-SSRS)
    • Laboratorium onderzoek (hematologie, stolling, klinische chemie inclusief lipiden panel en urine analyse)
    • Documentatie van gelijktijdig genomen medicatie
    E.5.1.1Timepoint(s) of evaluation of this end point
    96 Weeks
    96 weken
    E.5.2Secondary end point(s)
    • Observation of P-tau blood level concentration
    • To determine whether ANAVEX2-73 modifies cognition, behavior, or QoL, according to the following standardized measures commonly used in AD:
    - Change from baseline to week 96 in ADAS-Cog
    - Change from baseline to week 96 in ADCS-ADL
    - Change from baseline to week 96 in MMSE
    - Change from baseline to week 96 in NPI-Q
    - Change from baseline to week 96 in ZBI
    - Change from baseline to week 96 in QoL-AD
    • Observeren van de P-tau bloedspiegel
    • Bepalen of ANAVEX2-73 cognitie, gedrag of QoL wijzigt, volgens aan de volgende gestandaardiseerde metingen die vaak worden gebruikt in AD:
    - Verandering vanaf baseline tot week 96 in ADAS-Cog
    - Verandering vanaf baseline tot week 96 in ADCS-ADL
    - Verandering vanaf baseline tot week 96 in MMSE
    - Verandering vanaf baseline tot week 96 in NPI-Q
    - Verandering vanaf baseline tot week 96 in ZBI
    - Verandering vanaf baseline tot week 96 in QoL-AD.
    E.5.2.1Timepoint(s) of evaluation of this end point
    96 Weeks
    96 weken
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised No
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned2
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA8
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Australia
    Canada
    Germany
    Netherlands
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    Laatste patiënt, laatste visite,
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years2
    E.8.9.1In the Member State concerned months10
    E.8.9.1In the Member State concerned days13
    E.8.9.2In all countries concerned by the trial years4
    E.8.9.2In all countries concerned by the trial months10
    E.8.9.2In all countries concerned by the trial days4
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1Number of subjects for this age range: 0
    F.1.1.1In Utero No
    F.1.1.1.1Number of subjects for this age range: 0
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.2.1Number of subjects for this age range: 0
    F.1.1.3Newborns (0-27 days) No
    F.1.1.3.1Number of subjects for this age range: 0
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.4.1Number of subjects for this age range: 0
    F.1.1.5Children (2-11years) No
    F.1.1.5.1Number of subjects for this age range: 0
    F.1.1.6Adolescents (12-17 years) No
    F.1.1.6.1Number of subjects for this age range: 0
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 41
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 284
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception No
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally Yes
    F.3.3.6.1Details of subjects incapable of giving consent
    Patients may lose ability to give consent during trial or be unable to consent to the trial from start
    Patiënten kunnen het vermogen verliezen om toestemming te geven tijdens het onderzoek of kunnen vanaf het begin niet instemmen met het onderzoek
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state10
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 104
    F.4.2.2In the whole clinical trial 325
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Patients can continue to standard of care if they discontinue from the trial.
    Patiënten kunnen doorgaan met de standaardzorg als ze stoppen met de studie.
    G. Investigator Networks to be involved in the Trial
    G.4 Investigator Network to be involved in the Trial: 1
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2021-10-07
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2022-01-10
    P. End of Trial
    P.End of Trial StatusOngoing
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Apr 24 03:07:43 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA